Program
rocbrutinib
Also written as “Rocbrutinib”, “LP-168 tablet” and “LP-168”.
Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Sclerosis, Relapsing-Remitting · Waldenstrom Macroglobulinemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lupeng Pharmaceutical | 1411 open or running | phase 3since Jan 13, 2026 | Feb 22, 2021 | Mar 31, 2027phase 1 · NCT04993690 |
| Hansoh Pharmaceutical Group | 11 open or running | phase 2since Mar 4, 2025 | Mar 4, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 22, 2021First study: phase 1 study in Waldenstrom MacroglobulinemiaNew to Lupeng PharmaceuticalLupeng Pharmaceutical · NCT04775745 · 60 planned · United States
- Jul 27, 2021Phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT04993690 · 200 planned · China
- Jun 14, 2022Phase 1 study in Multiple SclerosisLupeng Pharmaceutical · NCT05432713 · 70 enrolled · China
- Jan 19, 2023Phase 2 study in Lymphoma, Mantle-CellLupeng Pharmaceutical · NCT05716087 · 62 enrolled · China
- Jun 15, 2023Phase 1 study in Lymphoma, Mantle-CellLupeng Pharmaceutical · NCT05917964 · 22 enrolled · China
- Nov 7, 2023Phase 1 study in Clinical PharmacologyLupeng Pharmaceutical · NCT06126861 · 6 enrolled · China
- Feb 1, 2024Phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT06251180 · 112 enrolled · China
- Mar 4, 2025Hansoh Pharmaceutical Group's first study: phase 2 study in Chronic UrticariaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06864507 · 150 planned · China
- Sep 16, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseLupeng Pharmaceutical · NCT07189065 · 150 planned · China
- Jan 13, 20262 phase 3 studiesPhase 3 reachedLupeng Pharmaceutical · NCT07377578, NCT07342478
- Jan 16, 2026Phase 1 study in Clinical PharmacologyLupeng Pharmaceutical · NCT07374224 · 28 planned · China
- Apr 22, 2026Phase 1 study in DLBCLLupeng Pharmaceutical · NCT07570017 · 42 planned · China
- May 20, 2026Phase 2 study in Lymphoma, Mantle-CellLupeng Pharmaceutical · NCT07609862 · 92 planned · China
- Aug 7, 2026Phase 2 study in Multiple Sclerosis, Relapsing-RemittingLupeng Pharmaceutical · NCT07776743 · 30 planned · China
Ahead
- Mar 31, 2027Primary completion: phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT04993690
- Jun 30, 2027Primary completion: phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT06251180
- Dec 31, 2027Primary completion: phase 1 study in DLBCLLupeng Pharmaceutical · NCT07570017
- Dec 31, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseLupeng Pharmaceutical · NCT07189065
TargetBeta
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07776743Multiple Sclerosis, Relapsing-Remitting · China | 2 | Recruiting | Lupeng Pharmaceutical | Jun 2028 | 30 |
| NCT07609862Lymphoma, Mantle-Cell · China | 2 | Recruiting | Lupeng Pharmaceutical | Jun 30, 2029 | 92 |
| NCT07570017DLBCL · China | 1 | Recruiting | Lupeng Pharmaceutical | Dec 31, 2027 | 42 |
| NCT07374224Clinical Pharmacology · China | 1 | Recruiting | Lupeng Pharmaceutical | Jun 30, 2026 | 28 |
| NCT07377578Lymphoma, Mantle-Cell · China | 3 | Recruiting | Lupeng Pharmaceutical | May 30, 2031 | 394 |
| NCT07342478Leukemia, B-Cell · United States, France | 3 | Recruiting | Lupeng Pharmaceutical | Oct 30, 2029 | 306 |
| NCT07189065Lymphoma, Large B-Cell, Diffuse · China | 2 | Recruiting | Lupeng Pharmaceutical | Dec 31, 2027 | 150 |
| NCT06864507Chronic Urticaria · China | 2 | Not yet recruiting | Hansoh Pharmaceutical Group | Sep 27, 2026 | 150 |
| NCT06251180Lymphoma, B-Cell · China | 1 | Active, not recruiting | Lupeng Pharmaceutical | Jun 30, 2027 | 112 |
| NCT06126861Clinical Pharmacology · China | 1 | Completed | Lupeng Pharmaceutical | Feb 2, 2024 | 6 |
| NCT05917964Lymphoma, Mantle-Cell · China | 1 | Completed | Lupeng Pharmaceutical | Aug 21, 2023 | 22 |
| NCT05716087Lymphoma, Mantle-Cell · China | 2 | Active, not recruiting | Lupeng Pharmaceutical | Dec 5, 2024 | 62 |
| NCT05432713Multiple Sclerosis · China | 1 | Completed | Lupeng Pharmaceutical | Nov 20, 2022 | 70 |
| NCT04993690Lymphoma, B-Cell · China | 1 | Recruiting | Lupeng Pharmaceutical | Mar 31, 2027 | 200 |
| NCT04775745Waldenstrom Macroglobulinemia · United States | 1 | Recruiting | Lupeng Pharmaceutical | Dec 31, 2027 | 60 |
How it is read
Names in the registry
- “Rocbrutinib”, 7 entries
- “LP-168 tablet”, 3 entries
- “LP-168”, 2 entries
- “Lacutoclax+Rocbrutinib”, 1 entry
- “Rocbrutinib tablets”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 4 studies
- Lymphoma, B-Cell, 2 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Multiple Sclerosis, Relapsing-Remitting, 1 study
- Waldenstrom Macroglobulinemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.